middle.news
Health Canada Greenlights Neuren’s Phase 3 Trial for Rare Syndrome Drug
9:57am on Monday 22nd of December, 2025 AEDT
•
Healthcare
Read Story
Health Canada Greenlights Neuren’s Phase 3 Trial for Rare Syndrome Drug
9:57am on Monday 22nd of December, 2025 AEDT
Key Points
Health Canada approves Clinical Trial Application for NNZ-2591 Phase 3 trial
Trial expansion enables Canadian clinical sites for Phelan-McDermid syndrome study
Second US site activated and enrolling patients in California
NNZ-2591 holds orphan drug designations in US and EU
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
NEU
OPEN ARTICLE